The board of directors of Nasdaq-listed company Anixa Biosciences has approved the purchase of Bitcoin as a reserve asset
According to PR Newswire, Anixa Biosciences, Inc. (NASDAQ: ANIX), a Nasdaq-listed company in the United States, announced that its board of directors has approved the purchase of Bitcoin as a treasury reserve asset with the aim of diversifying the company's assets and enabling Anixa to benefit from the potential long-term value of digital assets. It is reported that Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Barcelona Football Club criticized for signing a $22 million sponsorship deal with crypto company ZKP
Swedish payment giant Klarna's first stablecoin, KlarnaUSD, has been launched ahead of schedule
Bitcoin OG opens 5x ETH short position worth $15.04 million
Current mainstream CEX and DEX funding rates indicate the market remains broadly bearish
